Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAllogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences)

Drug Alias NamePBCAR-20A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPrecision Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrecision Biosciences Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A